Stefanie Flückiger-Mangual is the founder of TOLREMO therapeutics. TOLREMO therapeutics has raised $39M in total funding. Latest round: Series A.
Stefanie Flückiger-Mangual is the co-founder and Chief Executive Officer of TOLREMO therapeutics. The Swiss biotech company focuses on developing therapies to prevent non-genetic cancer drug resistance as it emerges. TOLREMO has raised a total of $39 million in Series A funding, with the latest round led by BioMedPartners AG and participation from Pierre Fabre Invest and existing investors. The company's lead candidate, TT125-802, is an orally available small molecule aimed at blocking critical transcriptional resistance pathways in cancer.
Full founder directory · Investor directory · Company funding database · Fundraising library